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Objectives: Surveillance for Middle East Respiratory Syndrome (MERS) has been undertaken in the UK
since September 2012. This study describes the surveillance outcomes in England from 2012 to 2018.
Study design: This was a descriptive study using surveillance data.
Methods: Local health protection teams in England report possible MERS cases to the National Infection
Service with clinical and laboratory data.
Results: A total of 1301 possible MERS cases were identified in the study period. Five cases were
laboratory-confirmed MERS. The majority of cases had travelled to Saudi Arabia (56.7%) and United Arab
Emirates (25.9%). Fifty-four percent of cases were men and 43.7% were women. The majority of cases
(65.1%) were aged 45 years or older. The number of tests increased in the period after Hajj each year.
Laboratory-confirmed alternative diagnoses were available for 513 (39.4%) cases; influenza was the most
common virus detected (n ¼ 255, 52.4%).
Conclusions: Our study highlights the importance of differential diagnosis of influenza and other res-
piratory pathogens and early influenza antiviral treatment.
Crown Copyright © 2020 Published by Elsevier Ltd on behalf of The Royal Society for Public Health. All
rights reserved.Coronaviruses are a large family of viruses that infect animals
and humans.1 Seasonal human coronavirus infections are typically
associated with cold or influenza-like illnesses. However, corona-
viruses have the potential to cause severe transmissible human
disease, as demonstrated by the severe acute respiratory syndrome
outbreak between 2002 and 20032 and the currently ongoing
coronavirus disease 2019 pandemic in 2020.3
TheMiddle East Respiratory Syndrome coronavirus (MERS-CoV)
is a betacoronavirus that was first identified in 2012.4 The first case
of Middle East Respiratory Syndrome (MERS) to be recognised
occurred in the Kingdom of Saudi Arabia (KSA) and was reported in
September 2012.5 In the same month, the UK reported the second
infection to be identified globally, in a Qatari national with a travel
history to KSA.4
MERS is not a notifiable disease in the UK, but an enhanced
surveillance programme for MERS has been in place in Englandx: þ44 20 8327 6585.
o).
evier Ltd on behalf of The Royal Ssince 2012, consisting of rapid identification and investigation of
possible cases presenting to the UK health system, awareness-
raising activities and implementation of rapid, enhanced respira-
tory infection prevention and control measures for suspected and
confirmed cases. This surveillance is important not only for early
detection and treatment of cases but also to prevent onward spread
of the disease, particularly outbreaks in hospital settings, which
have been seen elsewhere, especially in the Middle East and the
Republic of South Korea.6 This study describes the results of this
national MERS surveillance system in England from September
2012 to September 2018.
After the first imported MERS case in the UK was confirmed,4 in
September 2012, this MERS surveillance system was set up. Clini-
cians in England are requested to report possible cases that meet
the criteria set out in the national investigation algorithm7 to local
Public Health England (PHE) health protection teams (HPTs). The
details of the possible case definition and procedures of investi-
gation are listed in the national investigation algorithm.7 HPTs re-
cord possible cases via the national case and outbreak managementociety for Public Health. All rights reserved.
Table 1
Clinical and epidemiological characteristics among all investigated patients where
information available in the MERS-CoV surveillance system, England, 2012e2018
(n ¼ 1301).
Characteristics No. (%) patients No. (%) MERS-CoV
positive
Age group (years)
0-4 38 (2.9) 0 (0.0)
5-14 23 (1.8) 0 (0.0)
15-44 381 (29.3) 2 (0.5)
45-64 515 (39.6) 2 (0.4)
65þ 339 (26.1) 1 (0.3)
Unknown 5 (0.4) 0 (0.0)
Sex
Male 703 (54.0) 4 (0.6)
Female 568 (43.7) 1 (0.2)
Unknown 30 (2.3) 0 (0.0)
Clinical history
Fever 288/301 (95.7) 3 (1.0)
Cough 277/295 (93.9) 3 (1.1)
Pulmonary parenchymal
involvement
306/385 (79.5) 3 (1.0)
Acute respiratory distress syndrome 55/428 (12.9) 3 (5.5)
Mechanical ventilation 49/520 (9.4) 3 (6.1)
Extracorporeal membrane
oxygenation (ECMO)
7/483 (1.4) 3 (42.9)
Hospitalisation 607/627 (96.8) 4 (0.7)
Travel history to Middle East
countries in exposure perioda
before symptom onset
638/641 (99.5) 3 (0.5)
MERS-CoV, Middle East Respiratory Syndrome coronavirus.
a Exposure period was 10 days until June 2013 when it was increased to 14 days.
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national surveillance team, based at the National Infection Service.
The minimum data set form collects key data including de-
mographics, clinical details, travel and contact history and results of
laboratory testing. The possible case criteria have evolved over
time, particularly in 2018 when they were adapted to include
milder presentations.7 All diagnostic testing performed by PHE
public health laboratories is reported via the national laboratory
surveillance system, the respiratory DataMart database,8 and
confirmatory testing is performed solely by the PHE national
reference laboratory. Diagnostic testing for MERS-CoV RNA was
included in a routine panel of respiratory viruses tested for by
qualitative real-time reverse transcription polymerase chain reac-
tion, as described elsewhere. The routine panel included testing for
influenza A (both H1 and H3), influenza B, respiratory syncytial
virus (RSV), rhinoviruses, parainfluenza virus type 1e4, human
metapneumovirus (hMPV) and adenoviruses. Descriptive analyses
were carried out to summarise the epidemiological and laboratory
test results.
In total, 1301 patients in England were investigated and un-
derwent testing for possible MERS-CoV infection between 22
September 2012 and 30 September 2018. Of these, five tested
positive for MERS-CoV infection, including confirmatory testing by
the PHE national reference laboratory (3 imported cases and two
associated secondary transmission cases). The remaining 1296
possible cases tested negative. The first confirmedMERS case in the
UK was reported to the World Health Organization (WHO) on 22
September 2012, and details of this case have been published.4 The
most recent confirmed imported UK case was reported to theWHO
on 22 August 2018.9 Despite extensive contact tracing around these
imported cases, no healthcare workers caring for these cases have
been found to have been infected in England.
Of all the 1301 investigated patients that underwent laboratory
testing for MERS-CoV, 54.0% of them were men and 43.7% were
women (2.3% gender unknown); 39.6% of the cases were aged
45e64 years, 29.3% were 15e44 years and 26.1% were older than 65
years. The greatest number of tests was performed in London (281,
33.3%) based on patients’ residential addresses and available data
from 64.9% (844/1301) patients. The frequency of testing increased
in the period after the Hajj each year, usually between August and
October. The majority of cases investigated had a travel history to
KSA (56.7%, 362/638) and United Arab Emirates (UAE, 25.9%, 165/
638), whereas other cases had a travel history to Kuwait (4.4%, 28/
638), Qatar (4.1%, 26/638), Oman (2.4%, 15/638) and other countries
including Jordan (n¼ 13), Bahrain (n¼ 11), Iraq (n¼ 9), Iran (n¼ 6)
and Yemen (n ¼ 3).
The clinical and epidemiological characteristics among all
investigated patients (where information is available) are sum-
marised in Table 1. Fever (95.7%) and cough (93.9%) were the most
commonly reported symptoms. Pulmonary parenchymal involve-
ment was reported in the majority of investigated patients (79.5%).
Acute respiratory distress syndrome and the requirement for me-
chanical ventilation were reported in 12.9% and 9.4% of cases,
respectively, while extracorporeal membrane oxygenation (ECMO)
was administered in only 1.4% of investigated cases. Most cases
(96.8%) were reported to have been hospitalised.
As only a small number (n ¼ 5) of all possible cases (n ¼ 1301)
during the six-year study period were laboratory-confirmed MERS
(Table 2), the proportion of possible cases that were confirmed
according to a range of clinical criteria was mostly low. However,
the likelihood of MERS confirmation increased with disease
severity, with three of the seven possible cases who received ECMO
being confirmed as MERS-CoV infected.
Laboratory-confirmed alternative diagnoses were available for
513 (39.4%, 513/1301) of all possible cases. Influenza virus (alone or142as a coinfection with other pathogens) was the most common
pathogen (n ¼ 269, 52.4%), followed by rhinovirus (alone or as a
coinfection with other pathogens, n ¼ 158, 30.8%), adenovirus
(alone or as a coinfection with other pathogens, n ¼ 38, 7.4%),
parainfluenza virus (alone or as a coinfectionwith other pathogens,
n¼ 27, 5.3%), hMPV (alone or as a coinfectionwith other pathogens,
n ¼ 23, 4.5%), RSV (alone or as a coinfection with other pathogens
n ¼ 18, 3.5%) and Legionella species (n ¼ 15, 2.9%). Coinfections
with two ormore pathogens were found in 47 of 513 (9.2%) possible
cases. Among the five confirmedMERS cases, four had a coinfection
with either influenza (one case), or parainfluenza (two cases), or
adenovirus (one case). Among the 15 Legionella cases, ten were
returning travellers from the UAE, four from other Middle East
countries and one had unknown travel history. This is likely to
reflect the previously reported observations of Legionnaires’ dis-
ease associated with travel to Dubai, UAE.10
Discussion
We provide an overview of six-year enhanced MERS surveil-
lance in England. The vast majority (94.9%) of possible MERS cases
were those aged 15 years and older. More possible cases were
tested in London than in any other area in England, which may be
due to the larger population in London, its ethnically diverse pop-
ulation and associated travel patterns to the Middle East, including
Hajj pilgrimages. Differences in awareness regarding MERS be-
tween rural locations and cities might also play a role in possible
case reporting practice. We reported four confirmed cases in 2012
and 2013; and only limited, non-sustained secondary transmission
was associated with the second confirmed case. An additional
confirmed imported case was detected in August 2018.9 We found
that the likelihood of MERS confirmation increased with increasing
disease severity. We also found that MERS-CoV testing in England
peaked annually after the Hajj pilgrimage; therefore, laboratories,
hospitals and HPTs should be prepared for these peak activity pe-
riods, both in terms of requirements for testing and the additional
Table 2
Clinical details of the five laboratory-confirmed MERS-CoV cases, England, 2012e2018.
Case 1 Case 2 Case 3 (contact of Case 2) Case 4 (contact of Case 2) Case 5
Age group (years) 45e64 45e64 15e44 15e44 65þ
Sex Male Male Male Female Male
Onset month and year August 2012 January 2013 February 2013 February 2013 August 2018
Country of residence Qatar England England England Saudi Arabia
Fever Yes Yes Unknown Unknown Yes
Cough Yes Yes Unknown Unknown Yes
Pulmonary parenchymal involvement Yes Yes Yes No No
Acute respiratory distress syndrome Yes Yes Yes No No
Mechanical ventilation Yes Yes Yes No No
ECMO Yes Yes Yes No No
Hospitalisation Yes Yes Yes No Yes
Coinfection No Influenza A (H1N1)pdm09 Parainfluenza-2 No Adenovirus
Travel history Yes Yes No No Yes
Outcome Died Died Died Recovered Recovered
MERS-CoV, Middle East Respiratory Syndrome coronavirus; ECMO, extracorporeal membrane oxygenation.
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control measures. In addition, 39% of all possible cases had alter-
native diagnoses identified, mainly influenza, but also other
important pathogens such as Legionella species. We must empha-
sise that influenza and Legionella infections are not only important
but also treatable diseases.
The main limitation of this study is likely to be the incomplete
reporting. Minimum data set forms were only received for 57.0%
(742/1301) of all laboratory-tested cases. MERS is not notifiable
in the UK, and some possible cases are not reported to HPTs. In
part, this may be because not all persons tested met the ‘possible
case’ definition as advised by PHE.7 In addition, since July 2017,
MERS-CoV testing is no longer provided solely by PHE and other
clinical diagnostic laboratories were able to implement their own
testing; therefore, some possible cases may not have been re-
ported to the national surveillance systems. Another limitation is
that our database only contains records of positive laboratory
test results for other respiratory pathogens, such as influenza
and rhinovirus detections, but we do not have records of nega-
tive test results. Therefore, the proportion positive for non-
MERS-CoV pathogen infections could not be calculated in our
data.
Coinfections are not uncommon in MERS cases; therefore, a
positive detection of influenza or other pathogens does not exclude
MERS. This study shows the importance of a national surveillance
system not only for MERS but also for any other emerging severe
infections to ensure prompt investigation and implementation of
appropriate infection control measures and appropriate laboratory
testing. Transmission of MERS-CoV continues in the Middle East,
and on-going vigilance is required.Author statements
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